| |
|
Product Name:
|
Middle East Respiratory Syndrome Coronavirus, Recombinant Infectious Clone with T1015N Tissue Culture Adaptation Mutation (icMERS-CoV-T1015N)
|
|
Manufacturer:
|
BEI Resources
|
|
Taxonomy:
|
Virus Classification: Coronaviridae, Coronavirinae, Betacoronavirus
Agent: Middle East respiratory syndrome coronavirus (MERS-CoV)
Strain/Isolate: Recombinant infectious clone with T1015N tissue culture adaptation mutation (icMERS-CoV-T1015N)1,2
NR-48812 is a human group 2c betacoronavirus based on the MERS-CoV, EMC/2012 genome, engineered to contain the tissue culture adaptation mutation T1015N in the S glycoprotein gene.1,2
|
|
Material Provided:
|
Each vial contains approximately 1 mL of cell lysate and supernatant from Chlorocebus aethiops kidney epithelial cells (Vero: ATCC® CCL-81™) infected with icMERS-CoV-T1015N.
Note: If homogeneity is required for your intended use, please purify prior to initiating work.
|
|
Packing/Storage:
|
NR-48812 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.
|
|
Growth Conditions:
|
Host: Vero cells; ATCC® CCL-81™
Growth Medium: Dulbecco’s Modified Eagle’s Minimum modified to contain 4 mM L-glutamine, 4500 mg per liter glucose, 1 mM sodium pyruvate, and 1500 mg per liter sodium bicarbonate, supplemented with 2% fetal bovine serum, or equivalent
Infection: Cells should be 80% to 90% confluent
Incubation: 2 to 8 days at 37°C and 5% CO2
Cytopathic Effect: Refractile cell rounding and detachment, with some syncytia formation
|
|
Disclaimers:
|
You are authorized to use this product for research use only. It is not intended for human use. Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org. While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate. This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/ or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products. |
|
Patents or other restrictions:
|
Use of this material for any purpose by commercial or for-profit entities requires a license from The University of North Carolina at Chapel Hill prior to shipment. For more information on obtaining a license to use this material please contact the UNC-CH Office of Technology Development, 100 Europa Drive, Suite 430, Chapel Hill, North Carolina 27517, Phone (919) 966-3929, Email:otd@unc.edu
|
References:
|
1. Baric, R. S., Personal Communication.
2. Scobey, T., et al. “Reverse Genetics with a Full-Length Infectious cDNA of the Middle East Respiratory Syndrome Coronavirus.” Proc. Natl. Acad. Sci. USA 110 (2013): e5. PubMed: 24043791.
|
|
Citation:
|
Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Middle East Respiratory Syndrome Coronavirus, Recombinant Infectious Clone with T1015N Tissue Culture Adaptation Mutation (icMERS-CoV-T1015N), NR-48812."
|
|
Biosafety Level:
|
3
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.
|